Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids

Journal of Lipid Research

Volumn 51, Issue 12, 2010, Pages 3481-3490

  Morisseau, Christophe ^a   Inceoglu, Bora ^a   Schmelzer, Kara ^a   Tsai, Hsing Ju ^a   Jinks, Steven L ^b   Hegedus, Christine M ^a   Hammock, Bruce D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Central nervous system; Pain; Soluble epoxide hydrolase

Indexed keywords

DOCOSAHEXAENOIC ACID; DOCOSAHEXAENOIC ACID EPOXIDE; EPOXIDE; EPOXIDE HYDROLASE; FATTY ACID; ICOSAPENTAENOIC ACID; LIPID; LONG CHAIN FATTY ACID; MONOEPOXIDE; N 3 EPOXY FATTY ACID; OMEGA 3 FATTY ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FAT INTAKE; HYDROLYSIS; INFLAMMATION; ISOMER; KINETICS; MALE; NOCICEPTION; NONHUMAN; PAIN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PURIFICATION; SIGNAL TRANSDUCTION;

ANIMALS; CENTRAL NERVOUS SYSTEM; DISEASE MODELS, ANIMAL; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; EPOXIDE HYDROLASES; EPOXY COMPOUNDS; HYPERALGESIA; INFLAMMATION; KINETICS; MALE; PAIN; RATS; RATS, SPRAGUE-DAWLEY;

EID: 78650051942     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M006007     Document Type: Article

References (47)

1. Harris, W. S., P. M. Kris-Etherton, and K. A. Harris. 2008. Intakes of long-chain omega-3 fatty acid associated with reduced risk for death from coronary heart disease in healthy adults. Curr. Atheroscler. Rep. 10: 503-509.
2. Fedor, D., and D. S. Kelley. 2009. Prevention of insulin resistance by n-3 polyunsaturated fatty acids. Curr. Opin. Clin. Nutr. Metab. Care. 12: 138-146.
3. Goldberg, R. J., and J. Katz. 2007. A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. Pain. 129: 210-223.
4. Tjonahen, E., S. F. Oh, J. Siegelman, S. Elangovan, K. B. Percarpio, S. Hong, M. Arita, and C. N. Serhan. 2006. Resolvin E2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. Chem. Biol. 13: 1193-1202.
5. Fer, M., Y. Dréano, D. Lucas, L. Corcos, J. P. Salaün, F. Berthou, and Y. Amet. 2008. Metabolism of eicosapentaenoic and docosahexaenoic acids by recombinant human cytochromes P450.). Arch. Biochem. Biophys. 471: 116-125.
6. Harmon, S. D., X. Fang, T. L. Kaduce, S. Hu, V. Raj Gopal, J. R. Falck, and A. A. Spector. 2006. Oxygenation of omega-3 fatty acids by human cytochrome P450 4F3B: effect on 20-hydroxyeicosatetraenoic acid production. Prostaglandins Leukot. Essent. Fatty Acids. 75: 169-177.
7. Jump, D. B. 2002. The biochemistry of n-3 polyunsaturated fatty acids. J. Biol. Chem. 277: 8755-8758.
8. Capdevila, J. H., J. R. Falck, and R. C. Harris. 2000. Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. J. Lipid Res. 41: 163-181.
9. Das, U. N. 2006. Essential fatty acids: biochemistry, physiology and pathology. Biotechnol. J. 1: 420-439.
10. Gauthier, K. M., W. Yang, G. J. Gross, and W. B. Campbell. 2007. Roles of epoxyeicosatrienoic acids in vascular regulation and cardiac preconditioning. J. Cardiovasc. Pharmacol. 50: 601-608.
11. Serhan, C. N., and J. Savill. 2005. Resolution of inflammation: the beginning programs the end. Nat. Immunol. 6: 1191-1197.
12. Serhan, C. N., and N. Chiang. 2007. Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. Br. J. Pharmacol. 153: S200-S215.
13. Spector, A. A., and A. W. Norris. 2006. Action of epoxyeicosatrienoic acids on cellular function. Am. J. Physiol. Cell Physiol. 292: C996-C1012.
14. VanRollins, M., R. C. Baker, H. W. Sprecher, and R. C. Murphy. 1984. Oxidation of docosahexaenoic acid by rat liver microsomes. J. Biol. Chem. 259: 5776-5783.
15. VanRollins, M., P. D. Frade, and O. A. Carretero. 1989. Synthesis of epoxide and vicinal diol regioisomers from docosahexaenoate methyl esters. J. Lipid Res. 30: 275-286.
16. Yamane, M., A. Abe, and S. Yamane. 1994. High-performance liquid chromatography-thermospray mass spectrometry of epoxy polyunsaturated fatty acids and epoxyhydroxy polyunsaturated fatty acids from an incubation mixture of rat tissue homogenate. J. Chromatogr. A. 652: 123-136.
17. Barbosa-Sicard, E., M. Markovic, H. Honeck, B. Christ, D. N. Muller, and W. H. Schunck. 2005. Eicosapentaenoic acid metabolism by cytochrome P450 enzymes of the CYP2C subfamily. Biochem. Biophys. Res. Commun. 329: 1275-1281.
18. Lauterbach, B., E. Barbosa-Sicard, M-H. Wang, H. Honeck, E. Kargel, J. Theuer, M. L. Schwartzman, H. Haller, F. C. Luft, M. Gollasch, et al. 2002. Cytochrome P450-dependent eicosapentaenoic acid metabolites are novel BK channel activators. Hypertension. 39: 609-613. (Pubitemid 34165192)
19. Ye, D., D. Zhang, C. Oltman, K. Dellsperger, H-C. Lee, and M. VanRollins. 2002. Cytochrome p-450 epoxygenase metabolites of docosahexaenoate potently dilate coronary arterioles by activating large-conductance calcium-activated potassium channels. J. Pharmacol. Exp. Ther. 303: 768-776.
20. Morin, C., M. Sirois, V. Echave, E. Rizcallah, and E. Rousseau. 2009. Relaxing effects of 17(18)-EpETE on arterial and airway smooth muscles in human lung. Am. J. Physiol. Lung Cell. Mol. Physiol. 296: L130-L139.
21. McLennan, P., P. Howe, M. Abeywardena, R. Muggli, D. Raederstorff, M. Mano, T. Rayner, and R. Head. 1996. The cardiovascular protective role of docosahexaenoic acid. Eur. J. Pharmacol. 300: 83-89.
22. Hashimoto, M., K. Shinozuka, S. Gamoh, Y. Tanabe, M. S. Hossain, Y. M. Kwon, N. Hata, Y. Misawa, M. Kunitomo, and S. Masumura. 1999. The hypotensive effect of docosahexaenoic acid is associated with the enhanced release of ATP from the caudal artery of aged rats. J. Nutr. 129: 70-76. (Pubitemid 29044760)
23. Frenoux, J-M. R., E. D. Prost, J. L. Belleville, and J. L. Prost. 2001. A polyunsaturated fatty acid diet lowers blood pressure and improves antioxidant status in spontaneously hypertensive rats. J. Nutr. 131: 39-45.
24. VanRollins, M. 1995. Epoxygenase metabolites of docosahexaenoic and eicosapentaenoic acids inhibit platelet aggregation at concentrations below those affecting thromboxane synthesis. J. Pharmacol. Exp. Ther. 274: 798-804.
25. Newman, J. W., C. Morisseau, and B. D. Hammock. 2005. Epoxide hydrolases: their roles and interactions with lipid metabolism. Prog. Lipid Res. 44: 1-51.
26. Inceoglu, B., K. R. Schmelzer, C. Morisseau, S. L. Jinks, and B. D. Hammock. 2007. Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostaglandins Other Lipid Mediat. 82: 42-49.
27. Morisseau, C., and B. D. Hammock. 2008. Gerry Brooks and epoxide hydrolases: four decades to a pharmaceutical. Pest Manag. Sci. 64: 594-609.
28. Newman, J. W., T. Watanabe, and B. D. Hammock. 2002. The simultaneous quantification of cytochrome P450 dependent linoleate and arachidonate metabolites in urine by HPLC-MS/MS. J. Lipid Res. 43: 1563-1578.
29. Morisseau, C., M. H. Goodrow, J. W. Newman, C. E. Wheelock, D. L. Dowdy, and B. D. Hammock. 2002. Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem. Pharmacol. 63: 1599-1608.
30. Wixtrom, R. N., M. H. Silva, and B. D. Hammock. 1988. Affinity purification of cytosolic epoxide hydrolase using derivatized epoxy-activated Sepharose gels. Anal. Biochem. 169: 71-80.
31. Beetham, J. K., T. Tian, and B. D. Hammock. 1993. cDNA cloning and expression of a soluble epoxide hydrolase from human liver. Arch. Biochem. Biophys. 305: 197-201.
32. Inceoglu, B., S. L. Jinks, K. R. Schmelzer, T. Waite, I-H. Kim, and B. D. Hammock. 2006. Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain. Life Sci. 79: 2311-2319.
33. Yaksh, T. L., and T. A. Rudy. 1976. Chronic catheterization of the spinal subarachnoid space. Physiol. Behav. 17: 1031-1036.
34. Shearer, G. C., and J. W. Newman. 2009. Impact of circulating esterified eicosanoids and other oxylipins on endothelial function. Curr. Atheroscler. Rep. 11: 403-410.
35. Golovko, M. Y., and E. J. Murphy. 2008. An improved LC-MS/MS procedure for brain prostanoid analysis using brain fixation with head-focused microwave irradiation and liquid-liquid extraction. J. Lipid Res. 49: 893-902.
36. Engström, K., A. S. Saldeen, B. Yang, J. L. Mehta, and T. Saldeen. 2009. Effect of fish oils containing different amounts of EPA, DHA, and antioxidants on plasma and brain fatty acids and brain nitric oxide synthase activity in rats. Ups. J. Med. Sci. 114: 206-213.
37. Segel, I. H. 1975. Enzyme kinetics, behavior and analysis of rapid equilibrium and steady-state enzyme systems, Willey, New York, NY.
38. Morisseau, C., and B. D. Hammock. 2005. Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu. Rev. Pharmacol. Toxicol. 45: 311-333.
39. Bazan, N. 2005. Lipid signaling in neural plasticity, brain repair, and neuroprotection. Mol. Neurobiol. 32: 89-103.
40. Sura, P., R. Sura, A. E. Enayetallah, and D. F. Grant. 2008. Distribution and expression of soluble epoxide hydrolase in human brain. J. Histochem. Cytochem. 56: 551-559.
41. Marowsky, A., J. Burgener, J. R. Falck, J-M. Fritschy, and M. Arand. 2009. Distribution of soluble and microsomal epoxide hydrolase in the mouse brain and its contribution to cerebral epoxyeicosatrienoic acid metabolism. Neuroscience. 163: 646-661.
42. Iliff, J. J., and N. J. Alkayed. 2009. Soluble epoxide hydrolase inhibition: targeting multiple mechanisms of ischemic brain injury with a single agent. Future Neurol. 4: 179-199.
43. Inceoglu, B., S. L. Jinks, A. Ulu, C. M. Hegedus, K. Georgi, K. R. Schmelzer, K. Wagner, P. D. Jones, C. Morisseau, and B. D. Hammock. 2008. Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways. Proc. Natl. Acad. Sci. USA. 105: 18901-18906.
44. Reis, G. M., D. Pacheco, A. C. Perez, A. Klein, M. A. Ramos, and I. D. Duarte. 2009. Opioid receptor and NO/cGMP pathway as a mechanism of peripheral antinociceptive action of the cannabinoid receptor agonist anandamide. Life Sci. 85: 351-356.
45. Imig, J. D., and B. D. Hammock. 2009. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat. Rev. Drug Discov. 8: 794-805.
46. Perl, E. R. 2007. Ideas about pain, a historical view. Nat. Rev. Neurosci. 8: 71-80.
47. Smith, W. 1989. Eicosanoid nomenclature. Prostaglandins. 38: 125-133.